Several Hh pathway inhibitors that target SMO have demonstrated single-agent efficacy in patients with ligand-independent tumors[101-105], including vismodegib, which was approved by the FDA in 2012 for the treatment of patients with locally advanced or metastatic basal cell carcinoma[101,106]. Here, SMO is linked to basal cell carcinoma.